These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 17023996)

  • 1. The treatment of peptic ulcer disease.
    Louw JA; Marks IN
    Curr Opin Gastroenterol; 1999 Nov; 15(6):497-503. PubMed ID: 17023996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptic ulcer disease.
    Louw JA
    Curr Opin Gastroenterol; 2006 Nov; 22(6):607-11. PubMed ID: 17053437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals.
    Brzozowski T; Konturek PC; Sliwowski Z; Kwiecień S; Drozdowicz D; Pawlik M; Mach K; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():67-79. PubMed ID: 17033106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know?
    Kiltz U; Zochling J; Schmidt WE; Braun J
    Rheumatology (Oxford); 2008 Sep; 47(9):1342-7. PubMed ID: 18477642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients with gastric outlet obstruction related to peptic ulcer disease treated with endoscopic balloon dilatation and drug therapy.
    Cherian PT; Cherian S; Singh P
    Gastrointest Endosc; 2007 Sep; 66(3):491-7. PubMed ID: 17640640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
    Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
    Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helicobacter pylori and non-malignant diseases.
    Shirin H; Leja M; Niv Y
    Helicobacter; 2008 Oct; 13 Suppl 1():23-7. PubMed ID: 18783518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study.
    Tseng GY; Lin HJ; Fang CT; Yang HB; Tseng GC; Wang PC; Hung TL; Deng YC; Cheng YT; Huang CH
    Aliment Pharmacol Ther; 2007 Sep; 26(6):925-33. PubMed ID: 17767477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bleeding peptic ulcer. Prevalence of Helicobacter pylori and use of nonsteroidal anti-inflammatory drugs/acetylsalicylic acid].
    Vestergård A; Bredahl K; de Muckadell OB; Pedersen OB; Hansen JM
    Ugeskr Laeger; 2009 Jan; 171(4):235-9. PubMed ID: 19174039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of COX-2 and local cytokine expressions in gastric ulcer mucosa by H. pylori and NSAID.
    Wu CY; Wu MS; Chen YJ; Chen CJ; Lin JT; Chen GH
    Hepatogastroenterology; 2006; 53(71):797-803. PubMed ID: 17086892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori eradication: role of individual therapy constituents and therapy duration.
    Qasim A; O'Morain CA; O'Connor HJ
    Fundam Clin Pharmacol; 2009 Feb; 23(1):43-52. PubMed ID: 19207543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helicobacter pylori and non-malignant diseases.
    Rokkas T; Simsek I; Ladas S
    Helicobacter; 2007 Oct; 12 Suppl 1():20-2. PubMed ID: 17727456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
    Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
    Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
    Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA
    Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study.
    Thomsen RW; Riis A; Munk EM; Nørgaard M; Christensen S; Sørensen HT
    Am J Gastroenterol; 2006 Dec; 101(12):2704-10. PubMed ID: 17026569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years.
    Kadayifci A; Buyukhatipoglu H; Cemil Savas M; Simsek I
    Clin Ther; 2006 Nov; 28(11):1960-6. PubMed ID: 17213016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helicobacter pylori infection in peptic ulcer disease: the importance of smoking and ethnicity.
    Pillay KV; Htun M; Naing NN; Norsa'adah B
    Southeast Asian J Trop Med Public Health; 2007 Nov; 38(6):1102-10. PubMed ID: 18613553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicobacter pylori: testing and treatment.
    Talley NJ; Li Z
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):71-9. PubMed ID: 19072436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
    Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.